Gene signatures of inflammatory disorders that relate to the liver
This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis). These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.
1. A method, comprising:
a) providing a stool sample of a human subject; and
b) measuring the amount in the sample of the DNA of at least one bacterial gene selected from SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150.
2. The method of claim 1 , wherein the at least one bacterial gene is SEQ ID NO: 146.
3. The method of claim 2 , further comprising measuring the amount in the sample of the DNA of at least one bacterial gene selected from SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150.
4. The method of claim 1 , wherein the at least one bacterial gene is SEQ ID NO: 147.
5. The method of claim 1 , wherein the at least one bacterial gene is SEQ ID NO: 148.
6. The method of claim 1 , wherein the at least one bacterial gene is SEQ ID NO: 149.
7. The method of claim 1 , wherein the at least one bacterial gene is SEQ ID NO: 150.
8. The method of claim 1 , wherein the amount in the sample of the DNA of each of the bacterial genes SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, and SEQ ID NO: 150 is measured.
9. The method of claim 1 , wherein the human subject has steatohepatitis without fibrosis.
10. The method of claim 2 , wherein the human subject has steatohepatitis without fibrosis.
11. The method of claim 8 , wherein the human subject has steatohepatitis without fibrosis.
12. The method of claim 1 , wherein the human subject has NASH with fibrosis.
13. The method of claim 2 , wherein the human subject has NASH with fibrosis.
14. The method of claim 8 , wherein the human subject has NASH with fibrosis.
15. The method of claim 1 , wherein the human subject suffers from an inflammatory disease selected from the group consisting of: benign steatosis, non alcoholic steatohepatitis, liver fibrosis, cirrhosis, liver failure, liver cancer, and inflammatory bowel disease.
16. The method of claim 2 , wherein the human subject suffers from an inflammatory disease selected from the group consisting of: benign steatosis, non alcoholic steatohepatitis, liver fibrosis, cirrhosis, liver failure, liver cancer, and inflammatory bowel disease.
17. The method of claim 8 , wherein the human subject suffers from an inflammatory disease selected from the group consisting of: benign steatosis, non alcoholic steatohepatitis, liver fibrosis, cirrhosis, liver failure, liver cancer, and inflammatory bowel disease.
18. The method of claim 1 , wherein the amount in the sample of the DNA is measured by a process comprising DNA sequencing.
19. The method of claim 2 , wherein the amount in the sample of the DNA is measured by a process comprising DNA sequencing.
20. The method of claim 8 , wherein the amount in the sample of the DNA is measured by a process comprising DNA sequencing.